Can we predict neovascular complications?

Article

Many ophthalmic disorders give rise to neovascularization of the iris and neovascular glaucoma. Almost all of these disorders are characterized by retinal hypoxia and retinal capillary nonperfusion, the same factors involved in the development of retinal neovascularization. One of the most common causes is central retinal vein occlusion (CRVO), which is a visually disabling disease that is second in prevalence only to diabetic retinopathy.

Neovascular glaucoma occurs in 30% of patients with CRVO, 58 to 86% of whom suffer with the ischaemic form of CRVO and 4% with nonischaemic CRVO. Of the nonischaemic cases, however, 54% later go on to develop ischaemic CRVO. In practice, neovascular glaucoma provides a big challenge, with current therapies having a relatively low success rate, prevention is the most desirable form of intervention.

With this in mind, Shahsuvaryan investigated the systemic and ocular risk factor indicators for neovascular complications attributable to CRVO, in the hope of assisting clinicians to prevent neovascular glaucoma from developing.

Signs of CRVO included flame-shaped, dot or punctate retinal haemorrhages in all four quadrants of the retina, dilation and increased tortuosity of the retinal veins and optic disk swelling.

Data collection included demographic characteristics, associated ophthalmic and systemic conditions, blood pressure, complete blood count, erythrocyte sedimentation rate (ESR), blood sugar, blood coagulability (fibrinogen, recalcification time, plasma tolerance to heparin, prothrombin ratio) and visual acuity. Twenty-eight factors determined from clinical records were used to select statistically significant risk factors for neovascular glaucoma, using Bayes' theorem. Factors presented in figure 1 outline those factors that were selected for forecasting of neovascularization development, while the distribution of preliminary selected factors in patients with and without neovascular glaucoma is shown in figure 2. Based on the information rate calculation for each analysed factor, the author was able to elucidate the most significant neovascular glaucoma predictors (Table 1).

Analysis of the results showed that those patients who had suffered with systemic hypertension for a period of more than 10 years and those with a blood pressure reading of more than 200 mmHg, were more likely to develop neovascular glaucoma. The predictive ability of this neovascular glaucoma forecasting method was 88%, with a sensitivity of 85% and a specificity of 91%.

How do we predict it?

The results indicate that neovascular glaucoma is more likely to occur after CRVO in subjects with one or more of the factors listed in table 1. A follow-up schedule should be established depending on the patient's circumstances and these patients should be closely monitored for the earliest signs of iris and angle neovascularization.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
© 2025 MJH Life Sciences

All rights reserved.